Nurix Therapeutics, Inc. (NRIX): Cash & Equivalents
$246.96M
As of 2025-11-30
$67.69M
As of 2026-05-31
+56.5%
3-year compound annual growth
+15.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-11-30 | $246.96M | +124.5% | 2026-01-28, Balance as of period end |
| 2024-11-30 | $110.00M | +101.4% | 2026-01-28, Balance as of period end |
| 2023-11-30 | $54.63M | -15.3% | 2026-01-28, Balance as of period end |
| 2022-11-30 | $64.47M | -19.9% | 2025-01-28, Balance as of period end |
| 2021-11-30 | $80.51M | -32.5% | 2023-02-09, Balance as of period end |
| 2020-11-30 | $119.36M | +242.8% | 2022-01-28, Balance as of period end |
| 2019-11-30 | $34.82M | n/a | 2021-02-16, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $246.96M | +124.5% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $41.32M | -18.7% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $120.86M | -27.5% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.91M | -2.6% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $261.34M | +4.2% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $122.52M | +29.2% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $25.94M | +73.7% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $12.67M | -66.7% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $128.51M | -17.8% |
Compare NRIX, SPRY, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗